Scancell Holdings plc (SCNLF) Research
Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for metastatic melanoma; the SCIB2/iSCIB2 vaccine, currently being evaluated for its effectiveness against various solid tumors, such as non-small cell lung cancer; and Modi-1, which is progressing through Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is working on Modi-2, designed to target homocitrullinated cancer antigens. The company also has SCOV1 and SCOV2 COVIDITY in its portfolio, which are DNA vaccines developed to fight the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
Market snapshot
- Symbol
- SCNLF
- Price
- $0.28
- Day change
- 0.00%
- Market cap
- $214.5M
- P/E ratio
- -38.90x
- 52-week range
- 0.119-0.33487
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 4 months
Recent news
- Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up
Panmure Liberum holds its 'buy' rating and 32p target as FDA fast-track status adds regulatory momentum to compelling trial data. Scancell Holdings PLC...
- US banks set to deliver solid first quarter results amid macroeconomic uncertainty
Major US banks are poised to deliver solid first quarter results, though broader economic concerns may temper investor enthusiasm as earnings season begins,...
- Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal
Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9...
Peer companies
Open Scancell Holdings plc (SCNLF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.